Search

everythinglearnresearchcommunity

for

Search:↓

A user embraced their hair loss by choosing a buzzed hairstyle and received positive feedback on their appearance. Some suggested acceptance and self-care, while others discussed the potential of hair regrowth with treatments like finasteride and minoxidil.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

A 113 year old man who has more hair than most people, and the conversation is discussing potential genetic factors that may be responsible for this. Possible treatments such as dermarolling and minoxidil, finasteride, and RU58841 are mentioned.

People discuss hair loss treatments like minoxidil, finasteride, and dutasteride, sharing experiences and side effects. Opinions vary on combining treatments, with some skeptical and others reporting success.

A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

The conversation humorously discusses hair loss treatments, focusing on the use of finasteride and dutasteride, with some users debating the effectiveness and cost of different dosages. Some users mention using topical minoxidil and express concerns about side effects and availability of higher doses.

The conversation discusses using a combination of DHT gel, dutasteride, pyrilutamide, and minoxidil to promote beard growth while minimizing hair loss. Users suggest consulting a doctor and considering genetic factors before proceeding.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.